

CLINICAL PROBLEM-SOLVING
Calm before the Storm



Stay informed. Sign up to receive NEJM content delivered to your inbox.

PERSPECTIVE
Automatic Insurance Policies — Important Tools for Preventing Coverage Loss



EDITORIAL
Efficacy and Safety of Gene Therapy for β -Thalassemia

Perspective

Medication-Assisted Therapies — Tackling the Opioid-Overdose Epidemic


Nora D. Volkow, M.D., Thomas R. Frieden, M.D., M.P.H., Pamela S. Hyde, J.D., and Stephen S. Cha, M.D.

Article | **Figures/Media** | **Metrics**

5 References | 592 Citing Articles

May 29, 2014
N Engl J Med 2014; 370:2063-2066
DOI: 10.1056/NEJMp1402780

THE RATE OF DEATH FROM overdoses of prescription opioids in the United States more than quadrupled between 1999 and 2010 (see [graph](#)), far exceeding the combined death toll from cocaine and heroin overdoses.¹ In 2010 alone, prescription opioids were involved in 16,651 overdose deaths, whereas heroin was implicated in 3036. Some 82% of the deaths due to prescription opioids and 92% of those due to heroin were classified as unintentional, with the remainder being attributed predominantly to suicide or “undetermined intent.”



Opioid Sales, Admissions for Opioid-Abuse Treatment, and Deaths Due to Opioid Overdose in the United States, 1999–2010.

Rates of emergency department visits and substance-abuse treatment admissions related to prescription opioids have also increased markedly. In 2007, prescription-opioid abuse cost insurers an estimated \$72.5 billion — a substantial increase over previous years.² These health and economic costs are similar to those associated with other chronic diseases such as asthma and HIV infection.

These alarming trends led the Department of Health and Human Services (HHS) to deem prescription-opioid overdose deaths an epidemic and prompted multiple federal, state, and local actions.² The HHS efforts aim to simultaneously reduce opioid abuse and safeguard legitimate and appropriate access to these medications. HHS agencies are implementing a coordinated, comprehensive effort addressing the key risks involved in prescription-drug abuse, particularly opioid-related overdoses and deaths. These efforts focus on four main objectives: providing prescribers with the knowledge to improve their prescribing decisions and the ability to identify patients’ problems related to opioid abuse, reducing inappropriate access to opioids, increasing access to effective overdose treatment, and providing substance-abuse treatment to persons addicted to opioids.

A key driver of the overdose epidemic is underlying substance-use disorder.

Consequently, expanding access to addiction-treatment services is an essential component of a comprehensive response.²

Like other chronic diseases such as diabetes and hypertension, addiction is generally refractory to cure, but effective treatment and functional recovery are possible. Fortunately, clinicians have three types of medication-assisted therapies (MATs) for treating patients with opioid addiction: methadone, buprenorphine, and naltrexone (see [table](#)). Yet these medications are markedly underutilized. Of the 2.5 million Americans 12 years of age or older who abused or were dependent on opioids in 2012 (according to the National Survey on Drug Use and Health conducted by the Substance Abuse and Mental Health Services Administration [SAMHSA]), fewer than 1 million received MAT.

Characteristics of Medications for Opioid-Addiction Treatment.

When prescribed and monitored properly, MATs have proved effective in helping patients recover. Moreover, they have been shown to be safe and cost-effective and to reduce the risk of overdose. A study of heroin-overdose deaths in Baltimore between 1995 and 2009 found an association between the increasing availability of methadone and buprenorphine and an approximately 50% decrease in the number of fatal overdoses.³ In addition, some MATs increase patients’ retention in treatment, and they all improve social functioning as well as reduce the risks of infectious-disease transmission and of engagement in criminal activities. Nevertheless, MATs have been adopted in less than half of private-sector treatment programs, and even in programs that do offer MATs, only 34.4% of patients receive them.⁴

A number of barriers contribute to low access to and utilization of MATs, including a paucity of trained prescribers and negative attitudes and misunderstandings about addiction medications held by the public, providers, and patients. For decades, a common concern has been that MATs merely replace one addiction with another. Many treatment-facility managers and staff favor an abstinence model, and provider skepticism may contribute to low adoption of MATs.⁴ Systematic prescription of inadequate doses further reinforces the lack of faith in MATs, since the resulting return to opioid use perpetuates a belief in their ineffectiveness.

Policy and regulatory barriers are another concern. A recent report from the American Society of Addiction Medicine describing public and private insurance coverage for MATs highlights several policy-related obstacles that warrant closer scrutiny. These barriers include utilization-management techniques such as limits on dosages prescribed, annual or lifetime medication limits, initial authorization and reauthorization requirements, minimal counseling coverage, and “fail first” criteria requiring that other therapies be attempted first ([www.asam.org/docs/advocacy/Implications-for-Opioid-Addiction-Treatment](#)). Although these policies may be intended to ensure that MAT is the best course of treatment, they may hinder access and appropriate care. For example, maintenance MAT has been shown to prevent relapse and death but is strongly discouraged by lifetime limits.⁵

In addition, although Medicaid covers buprenorphine and methadone in every state, some Medicaid programs or their managed-care organizations apply the utilization-management policies described above. Most commercial insurance plans also cover some opioid-addiction medications — most commonly buprenorphine — but coverage is generally limited by similar policies, and access to care may be limited to in-network providers. Few private insurance plans provide coverage for the depot injection formulation of naltrexone, and most do not cover methadone provided through opioid treatment programs.

Implementation of the Affordable Care Act (ACA) will increase access to care for many Americans, including persons with addiction. This expansion builds on the Mental Health Parity and Addiction Equity Act, which requires insurance plans that offer coverage for mental health or substance-use disorders to provide the same level of benefits that they do for general medical treatment. The ACA significantly extends the reach of the parity law’s requirements, ensuring that more Americans have coverage for mental health and substance-use disorders and that coverage complies with the federal parity requirements. These reforms present new opportunities for reducing prescription-opioid abuse and its consequences by expanding the number of high-risk people who receive MATs through either public or private insurance. The importance of access to MATs and other treatment services for substance-use disorder is underscored by the recent recognition of increased heroin use; what may be less widely recognized is that the majority of these new heroin users initially abused prescription opioids before shifting to heroin.

HHS agencies are actively collaborating with public and private stakeholders in efforts to expand access to and improve utilization of MATs, in tandem with other targeted approaches to reducing opioid overdoses.² For example, the National Institute on Drug Abuse (NIDA) is funding research to improve delivery of MATs to vulnerable populations, including those in the criminal justice system. NIDA is also working to develop new pharmacologic treatments for opioid addiction and helping to fund “user friendly” delivery systems for naloxone (i.e., intranasal rather than injection). SAMHSA is encouraging MAT use in its state funding of substance-abuse treatment programs through the Substance Abuse Prevention and Treatment Block Grant and regulatory oversight of methadone and buprenorphine for opioid addiction. Furthermore, SAMHSA supports production and dissemination of educational resources to MAT prescribers, as well as an “Opioid Overdose Toolkit” to educate first responders, treatment providers, and patients about ways to prevent and intervene in opioid-overdose cases.

The Centers for Disease Control and Prevention is working to empower states to implement comprehensive strategies, including MATs, for preventing prescription-drug overdoses. These strategies focus primarily on addressing the overdose epidemic through enhanced surveillance, effective policies, and clinical practices that establish statewide prescribing norms. Such efforts can be enhanced by using data sources to identify and intervene in cases of patients or providers who fall outside those norms. And the Centers for Medicare and Medicaid Services is working to enhance access to MATs by Medicaid programs through improved benefit design and application of the Mental Health Parity and Addiction Equity Act. But to be successful, all these initiatives require the active engagement and participation of the medical community.

The epidemic of prescription-opioid overdose is complex. Expanding access to MATs is a crucial component of the effort to help patients recover. It is also necessary, however, to implement primary prevention policies that curb the inappropriate prescribing of opioid analgesics — the key upstream driver of the epidemic — while avoiding jeopardizing critical or even lifesaving opioid treatment when it is needed. Essential steps for physicians will be to reduce unnecessary or excessive opioid prescribing, routinely check data from prescription-drug-monitoring programs to identify patients who may be misusing opioids, and take full advantage of effective MATs for people with opioid addiction.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

This article was published on April 23, 2014, and updated on May 1, 2014, at NEJM.org.

Author Affiliations

From the National Institute on Drug Abuse, National Institutes of Health, Bethesda (N.D.V.), the Substance Abuse and Mental Health Services Administration, Rockville (P.S.H.), and the Center for Medicaid and CHIP Services, Centers for Medicare and Medicaid Services, Baltimore (S.S.C.) — all in Maryland; and the Centers for Disease Control and Prevention, Atlanta (T.R.F.).

Supplementary Material

[Disclosure Forms](#) | PDF | 173KB

References (5)

Citing Articles (592)

More about | [ADDICTION](#) | [DRUGS, DEVICES, AND THE FDA](#) | [PRIMARY CARE/HOSPITALIST/CLINICAL PRACTICE](#) | [PAIN](#)

ADVERTISEMENT

Beginning March 2022 Apply Today

HARVARD MEDICAL SCHOOL Postgraduate Medical Education

NEJM CareerCenter

PHYSICIAN JOBS FEBRUARY 7, 2022

- Family Medicine** Utah
Family Medicine - Mt. Pleasant, UT - Mt. Pleasant Clinic
- Gastroenterology** New York
BE/BC Gastroenterologists, Long Island, NY
- Psychiatry** Philadelphia, Pennsylvania
Adult Psychiatrist
- Cardiology** New Jersey
CARDIOLOGIST
- Hematology / Oncology** Kennewick, Washington State
Radiation Oncologist
- Neurology** Florida
General Neurology Baptist Outpatient, Downtown

This week's issue of the **New England Journal of Medicine**

READ NOW

More Perspective

PERSPECTIVE FEB 05
Roulette
T.J. McGarrity

PERSPECTIVE FEB 05
Beyond Diversity — Time for New Models of Health
J.L. Delgado

PERSPECTIVE FEB 05
Racial Biology and Medical Misconceptions
A. Deyrup and J.L. Graves, Jr.

Most Viewed

PERSPECTIVE FEB 2, 2022
Challenges in Inferring Intrinsic Severity of the SARS-CoV-2 Omicron Variant
R. P. Bhattacharyya and W. P. Hanage

REVIEW ARTICLE FEB 3, 2022
Fever of Unknown Origin
G. Haidar and N. Singh

ORIGINAL ARTICLE JAN 27, 2022
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
R. L. Gottlieb and Others

More from the week of May 29, 2014

PERSPECTIVE
Embracing Oral Cholera Vaccine — The Shifting Response to Cholera
J.W. Pape and V. Rouzier

ORIGINAL ARTICLE
A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
T.E. King, Jr., and Others

ORIGINAL ARTICLE
Use of Vibrio cholerae Vaccine in an Outbreak in Guinea
F.J. Luquero and Others

Tap into groundbreaking research and clinically relevant insights

[SUBSCRIBE](#)

Already a subscriber? [Activate your online access.](#)